These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29557805)

  • 1. Role of Direct-Acting Antivirals in Hepatitis C Virus-Positive Castleman Disease.
    Tahir M; Charles L
    Am J Ther; 2018; 25(6):e733-e734. PubMed ID: 29557805
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals.
    Parlati L; Sirmai L; Dupuy CA; Glotz D; Pol S
    Clin Res Hepatol Gastroenterol; 2019 Apr; 43(2):e18-e19. PubMed ID: 30293896
    [No Abstract]   [Full Text] [Related]  

  • 3. New Indications for Harvoni.
    Med Lett Drugs Ther; 2016 Jan; 58(1485):6. PubMed ID: 27099890
    [No Abstract]   [Full Text] [Related]  

  • 4. Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.
    Huysentruyt K; Stephenne X; Varma S; Scheers I; Leclercq G; Smets F; Sokal EM
    Liver Transpl; 2017 Apr; 23(4):552-553. PubMed ID: 28006874
    [No Abstract]   [Full Text] [Related]  

  • 5. Two Antiviral Drugs Approved For Adolescents With HCV.
    Aschenbrenner DS
    Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749879
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful evolution of morphea after hepatitis C virus eradication with direct-acting antiviral agent treatment.
    Guerra Romero AR; Pérez Figueras M; Alonso López S
    Rev Esp Enferm Dig; 2019 Dec; 111(12):973. PubMed ID: 31696725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir.
    Sise ME
    Hepatology; 2017 Oct; 66(4):1335-1337. PubMed ID: 28650558
    [No Abstract]   [Full Text] [Related]  

  • 8. Sovaldi dilemma likely to get worse.
    Carroll J
    Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
    [No Abstract]   [Full Text] [Related]  

  • 9. Remission of Psoriasis After Treatment of Chronic Hepatitis C Virus Infection With Direct-Acting Antivirals.
    Enomoto M; Tateishi C; Tsuruta D; Tamori A; Kawada N
    Ann Intern Med; 2018 May; 168(9):678-680. PubMed ID: 29335738
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
    Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
    Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harvoni (ledipasvir and sofosbuvir) for hepatitis C.
    Mullins C; Gibson W; Klibanov OM
    Nurse Pract; 2015 Nov; 40(11):22-6. PubMed ID: 26474199
    [No Abstract]   [Full Text] [Related]  

  • 12. Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports.
    Chamorro-de-Vega E; Gimenez-Manzorro A; Sanjurjo M;
    Med Clin (Barc); 2018 Jul; 151(2):85-86. PubMed ID: 29295791
    [No Abstract]   [Full Text] [Related]  

  • 13. The paediatric population: the forgotten element to eliminating hepatitis C virus.
    Lens S; Lazarus JV
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):334-335. PubMed ID: 31954440
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapy for hepatitis C--the costs of success.
    Hoofnagle JH; Sherker AH
    N Engl J Med; 2014 Apr; 370(16):1552-3. PubMed ID: 24725236
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful therapy with Ledipasvir/Sofosbuvir for hepatitis C reactivation in a hematopoietic stem cell transplant recipient.
    Wahba MR; Surapaneni M; Chandrasekar PH
    Leuk Lymphoma; 2016 Nov; 57(11):2693-5. PubMed ID: 26998960
    [No Abstract]   [Full Text] [Related]  

  • 16. Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.
    Graf Einsiedel H; Christiansen H; Wiegand J
    Pediatr Infect Dis J; 2016 Dec; 35(12):1373. PubMed ID: 27832030
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
    Gray E; O'Leary A; Bergin C; Cannon M; Courtney G; Crosbie O; De Gascun CF; Fanning LJ; Feeney E; Houlihan DD; Kelleher B; Lambert JS; Lee J; Mallon P; McConkey S; McCormick A; McKiernan S; McNally C; Murray F; Sheehan G; Stewart S; Walsh C; Norris S;
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):593-601. PubMed ID: 28276815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging options for treating hepatitis C infection.
    Fantasia HC
    Nurs Womens Health; 2015; 19(2):183-7. PubMed ID: 25900589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms.
    Nardelli S; Riggio O; Rosati D; Gioia S; Farcomeni A; Ridola L
    World J Gastroenterol; 2019 Dec; 25(48):6928-6938. PubMed ID: 31908396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.
    Mattingly Ii TJ; Heil EL; Hoke KS
    J Health Care Poor Underserved; 2017; 28(2):621-625. PubMed ID: 28529212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.